Shares of Exact Sciences Corporation (NasdaqCM:EXAS) surged 25% on late November 19, 2025, after a report said the conglomerate Abbott Laboratories (NYSE:ABT) is close to a deal to acquire the company. Neither Abbott nor Exact Sciences immediately responded to a request for comment. The Bloomberg report didn?t include any financial terms of a potential deal.
Abbott Laboratories specializes in the research, development, manufacturing and marketing of pharmaceutical and medical products. Net sales break down by family of products as follows:
- vascular devices (26.7%): endoprosthetic systems, dilation catheters, arterial closures, etc.;
- diagnostic systems and instruments 22.3%);
- nutrition products (20%): pediatric nutrition products, nutritional supplements, and dietetic products;
- medicine (12.4%): anesthetics, antiviral products, antibiotics, inhibitors, anti-inflammatories, etc.;
- other (18.6%).
Net sales are distributed geographically as follows: the United States (38.9%), Germany (6.1%), China (5%), India (4.3%), Switzerland (4.2%), Japan (3.4%), the Netherlands (2.7%) and other (35.4%).
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
